Published in Drug Week, December 16th, 2005
There was no revenue for the quarter ended September 30, 2005 as compared to $954,000 in the third quarter of 2004. The change in revenue reflects the fact that Oxis operations are no longer consolidated with our results effective March 1, 2005, and all revenue for the prior periods was derived from Oxis.
Research and development costs were $5,135,000 and $6,054,000 for the 3 months ended...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.